48-wk Open Label Phase IIIb to Evaluate Efficacy and Safety

NCT00654602 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1500

Last updated 2009-05-28

No results posted yet for this study

Summary

The purpose of this study is to assess the efficacy and safety of rosuvastatin in reducing low density lipoprotein cholesterol levels to internationally recognised goals in subjects with dyslipidaemia.

Conditions

  • Dyslipidaemia

Interventions

DRUG

Rosuvastatin

BEHAVIORAL

Maintenance of specific diet

Sponsors & Collaborators

Principal Investigators

  • Dr. Evan Stein · Metabolic & Athersclerotic research centre, USA

  • Russell Esterline · AstraZeneca

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-02-28
Completion
2004-11-30

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00654602 on ClinicalTrials.gov